PepperLime Health Acquisition Corporation Announces the Separate Trading of Its Class A Ordinary Shares and Redeemable Warrants Commencing December 9, 2021
SAN FRANCISCO, December 6, 2021 (Newswire.com) - PepperLime Health Acquisition Corporation (Nasdaq: PEPLU) (the "Company") today announced that, commencing December 9, 2021, holders of the units sold in the Company's initial public offering of 15,000,000 units completed on October 19, 2020, and a subsequent issuance of an additional 2,000,000 units completed on October 29, 2021 pursuant to the partial exercise by the underwriters of their over-allotment option in connection with the initial public offering, may elect to separately trade the shares of Class A ordinary shares and redeemable warrants included in the units. Those units not separated will continue to trade on the Nasdaq Stock Market LLC ("Nasdaq") under the symbol "PEPLU," and the shares of Class A ordinary shares and redeemable warrants that are separated will trade on Nasdaq under the symbols "PEPL" and "PEPLW," respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into shares of Class A ordinary shares and redeemable warrants.
The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
The units were initially offered by the Company in an underwritten offering. Oppenheimer & Co. Inc. acted as the sole book-running manager in the offering. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Oppenheimer & Co. Inc., Attn: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, telephone: (212) 667-8055 or email: EquityProspectus@opco.com.
A registration statement relating to the securities became effective on October 14, 2020 in accordance with Section 8(a) of the Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward Looking Statements
This press release may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company's management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company's filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus relating to the Company's initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Contact:
PepperLime Health Acquisition Corporation
www.pepperlimehealth.com
Ramzi Haidamus
(415) 263-9939
Source: PepperLime Health